Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis

Journal of Infectious Diseases

Volumn 195, Issue 9, 2007, Pages 1365-1372

  Braff, Marissa H ^a,b   Jones, Amanda L ^a,b   Skerrett, Shawn J ^c   Rubens, Craig E ^a,b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; CATHELICIDIN; OPSONIN; POLYPEPTIDE ANTIBIOTIC AGENT; STAPHYLOKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; CONTROLLED STUDY; FIBRINOLYSIS; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; MOUSE; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL PROTEINS; BRONCHOALVEOLAR LAVAGE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYSIS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATORS; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCUS AUREUS;

EID: 34247485785     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513277     Document Type: Article

References (50)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
2. Chambers HF. The changing epidemiology of Staphylococcus aureus?Emerg Infect Dis 2001; 7:178-82.
3. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(Suppl 2):S114-32.
4. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphy lococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10:505-20.
5. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344:11-6.
6. Zhang P, Summer WR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. Immunol Rev 2000; 173:39-51.
7. Fedtke I, Gotz F, Peschel A. Bacterial evasion of innate host defenses - the Staphylococcus aureus lesson. Int J Med Microbiol 2004; 294:189-94.
8. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. Staph ylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 2004; 172: 1169-76.
9. Rooijakkers SH, van Wamel WJ, Ruyken M, van Kessel KP, van Strijp JA. Anti-opsonic properties of staphylokinase. Microbes Infect 2005; 7:476-84.
10. Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood 1994; 84:680-6.
11. Bokarewa MI, Jin T, Tarkowski A. Staphylococcus aureus: staphylokinase. Int J Biochem Cell Biol 2005; 38:504-9.
12. Parry MA, Zhang XC, Bode I. Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. Trends Biochem Sci 2000; 25:53-9.
13. Bokarewa M, Tarkowski A. Human alpha-defensins neutralize fibrinolytic activity exerted by staphylokinase. Thromb Haemost 2004; 91: 991-9.
14. Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest 2002; 109:693-7.
15. Travis SM, Conway BA, Zabner J, et al. Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 1999; 20: 872-9.
16. Agerberth B, Grunewald J, Castanos-Velez E, et al. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care Med 1999; 160:283-90.
17. Singh PK, Tack BF, McCray PB Jr, Welsh MJ. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol 2000; 279:L799-805.
18. Cole AM, Liao HI, Stuchlik O, Tilan J, Pohl J, Ganz T. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 2002; 169:6985-91.
19. Schnapp D, Harris A. Antibacterial peptides in bronchoalveolar lavage fluid. Am J Respir Cell Mol Biol 1998; 19:352-6.
20. Bera A, Herbert S, Jakob A, Vollmer W, Gotz F. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staph ylococcus aureus. Mol Microbiol 2005; 55:778-87.
21. Schroder JM. Epithelial antimicrobial peptides: innate local host response elements. Cell Mol Life Sci 1999; 56:32-46.
22. Harder J, Bartels J, Christophers E, Schroder JM. A peptide antibiotic from human skin. Nature 1997; 388:416.
23. Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/ hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998; 95:9541-6.
24. Midorikawa K, Ouhara K, Komatsuzawa H, et al. Staphylococcus aureus susceptibility to innate antimicrobial peptides, beta-defensins and CAP18, expressed by human keratinocytes. Infect Immun 2003; 71:3730-9.
25. Dorschner RA, Lopez-Garcia B, Peschel A, et al. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J 2006; 20:35-42.
26. Nagaoka I, Hirota S, Yomogida S, Ohwada A, Hirata M. Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res 2000; 49:73-9.
27. Chen X, Niyonsaba F, Ushio H, et al. Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J Dermatol Sci 2005; 40:123-32.
28. Schaller-Bals S, Schulze A, Bals R. Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am J Respir Crit Care Med 2002; 165:992-5.
29. Beisswenger C, Bals R. Antimicrobial peptides in lung inflammation. Chem Immunol Allergy 2005; 86:55-71.
30. Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 1999; 67:6084-9.
31. Bals R, Weiner DJ, Meegalla RL, Wilson JM. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 1999; 103:1113-7.
32. Novick R. Properties of a cryptic high-frequency transducing phage in Staphylococcus aureus. Virology 1967; 33:155-66.
33. Peng HL, Novick RP, Kreiswirth B, Kornblum J, Schlievert P. Cloning, characterization, and sequencing of an accessory gene regulator (agr) in Staphylococcus aureus. J Bacteriol 1988; 170:4365-72.
34. Skerrett SJ, Liggitt HD, Hajjar AM, Wilson CB. Cutting edge: myeloid differentiation factor 88 is essential for pulmonary host defense against Pseudomonas aeruginosa but not Staphylococcus aureus. J Immunol 2004; 172:3377-81.
35. Christner RB, Boyle MD. Role of staphylokinase in the acquisition of plasmin(ogen)-dependent enzymatic activity by staphylococci. J Infect Dis 1996; 173:104-12.
36. Wolberg AS, Gabriel DA, Hoffman M. Analyzing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis 2002; 13:533-9.
37. Choi G, Schultz MJ, van Till JW, et al. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004; 24:786-9.
38. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia - a review. Crit Care Med 2006; 34:871-7.
39. Jin T, Bokarewa M, McIntyre L, et al. Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient Staphylo coccus aureus strains. J Med Microbiol 2003; 52:919-23.
40. Gladysheva IP, Turner RB, Sazonova IY, Liu L, Reed GL. Coevolutionary patterns in plasminogen activation. Proc Natl Acad Sci USA 2003; 100: 9168-72.
41. Okada K, Ueshima S, Tanaka M, Fukao H, Matsuo O. Analysis of plasminogen activation by the plasmin-staphylokinase complex in plasma of [alpha]2-antiplasmin-deficient mice. Blood Coagul Fibrinolysis 2000; 11: 645-55.
42. Marcum JA, Kline DL. Species specificity of streptokinase. Comp Biochem Physiol B 1983; 75:389-94.
43. Li Z, Ploplis VA, French EL, Boyle MD. Interaction between group A streptococci and the plasmin(ogen) system promotes virulence in a mouse skin infection model. J Infect Dis 1999; 179:907-14.
44. Rezcallah MS, Boyle MD, Sledjeski DD. Mouse skin passage of Streptococcus pyogenes results in increased streptokinase expression and activity. Microbiology 2004; 150:365-71.
45. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004; 23:327-33.
46. Khil J, Im M, Heath A, et al. Plasminogen enhances virulence of group A streptococci by streptokinase-dependent and streptokinase-independent mechanisms. J Infect Dis 2003; 188:497-505.
47. Sun H, Ringdahl U, Homeister JW, et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 2004; 305:1283-6.
48. Gallo RL, Murakami M, Ohtake T, Zaiou M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 2002; 110:823-31.
49. Ohlenschlager O, Ramachandran R, Guhrs KH, Schlott B, Brown LR. Nuclear magnetic resonance solution structure of the plasminogen-activator protein staphylokinase. Biochemistry 1998; 37:10635-42.
50. Kikuchi T, Hasumi K. Enhancement of plasminogen activation by surfactin C: augmentation of fibrinolysis in vitro and in vivo. Biochim Biophys Acta 2002; 1596:234-45.